Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Will “Actively Promote” Synthroid Despite Generic Entrants

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will not cease marketing efforts in the face of AB-rated levothyroxine generics from Mylan and Sandoz. U.S. Synthroid sales jumped 24% during the quarter due to increased share and favorable year-over-year comparisons.

You may also be interested in...



Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns

Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.

Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns

Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.

Synthroid Holding 75% Of Its Pre-Generic Script Share, Abbott Says

Script share for the levothyroxine brand is "within our range of expectations" since AB-rated generics entered the market, CFO Freyman says. Abbott predicted generic erosion for Synthroid would be less than that for other drugs due, in part, to the product's narrow therapeutic range.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel